Apophysomyces elegans : Epidemiology, Amplified Fragment Length Polymorphism Typing, and In Vitro Antifungal Susceptibility Pattern
- 1 December 2010
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 48 (12), 4580-4585
- https://doi.org/10.1128/jcm.01420-10
Abstract
Apophysomyces elegans is an emerging pathogen in India. We planned the present study to analyze the clinical pattern of the disease, to perform molecular strain typing, and to determine the in vitro activities of eight antifungal drugs against A. elegans. A total of 16 clinical and two environmental A. elegans isolates were included in the study. The clinical histories of the patients were noted. MICs or minimum effective concentrations (MECs) were determined for antifungal drugs by microdilution testing in accordance with CLSI standard M38-A2 guidelines. Of 16 patients, seven had rhino-cerebral, five had cutaneous, and three had renal zygomycosis. One patient had osteomyelitis. Uncontrolled diabetes was observed in 63% of the patients. Amplified fragment length polymorphism (AFLP) analysis divided the strains into two clearly different clades. The fingerprints of the environmental strains (including the type strain) were clearly different from those of the clinical strains. The MIC50s and MIC90s for amphotericin B, itraconazole, posaconazole, and isavuconazole were 2 and 4, 1 and 2, 0.5 and 1, and 2 and 4 μg/ml, respectively. The strains had high MICs for fluconazole, voriconazole, and echinocandins. The study indicates a possible change in the clinical pattern of zygomycosis due to A. elegans in India. The fungus caused not only cutaneous or subcutaneous infection but also other deep-seated infections, and the disease is commonly associated with uncontrolled diabetes. The AFLP patterns show a clear difference between environmental and clinical strains. Posaconazole is the most active drug against the isolates, followed by itraconazole. The MICs of amphotericin B against A. elegans were higher than those of the other drugs.Keywords
This publication has 40 references indexed in Scilit:
- In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2009
- Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida , Aspergillus , Fusarium , and Scedosporium SpeciesAntimicrobial Agents and Chemotherapy, 2008
- Favorable outcome of amphotericin B treatment of zygomycotic necrotizing fascitis caused by Apophysomyces elegansInternational Journal of Dermatology, 2008
- In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal AgentsAntimicrobial Agents and Chemotherapy, 2007
- Posaconazole Treatment for Apophysomyces elegans Rhino-Orbital Zygomycosis following Trauma for a Male with Well-Controlled DiabetesJournal of Clinical Microbiology, 2007
- Aspergillus strain typing in the genomics eraStudies in Mycology, 2007
- Rhino-Orbitocerebral Mucormycosis Caused by Apophysomyces elegansJournal of Clinical Microbiology, 2006
- Apophysomyces elegans : an Emerging Zygomycete in IndiaJournal of Clinical Microbiology, 2003
- Amplification-Based Nucleic Acid Scanning Techniques to Assess Genetic Polymorphism inCandidaCritical Reviews in Microbiology, 2003